Bonothyrk is a parathyroid-specific peptide bioregulator developed within the Khavinson research lineage. The parathyroid glands — four small glands behind the thyroid — control calcium and phosphorus balance through parathyroid hormone (PTH) secretion. Healthy parathyroid function is critical for bone integrity, neuromuscular signalling and cardiovascular function.
As we age, parathyroid responsiveness can decline, contributing to subclinical calcium imbalance and accelerated bone density loss. Bonothyrk supplies short peptide signals derived from parathyroid tissue, designed to support physiological gland function and downstream calcium-phosphorus homeostasis.
Clinical observation studies in the bioregulator literature suggest Bonothyrk may benefit adults experiencing osteopenia, post-menopausal bone density concerns, and chronic fatigue patterns linked to mineral imbalance. It is often paired with Sigumir (cartilage peptide) and vitamin D3+K2 for comprehensive bone-mineral protocols.
Recommended use: 1–2 capsules per day for a 30-day cycle, repeated 2–3 times per year. Bonothyrk is not appropriate for individuals with known parathyroid disorders without physician supervision, since active hyperparathyroidism or hypercalcaemia requires medical management.
PeptideComb manufactures Bonothyrk in Germany under pharmaceutical-grade conditions. Each batch is tested for peptide identity, microbial safety and label accuracy. The capsules are easy to swallow and gentle on the digestive system when taken with a small amount of water.
